{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:10:50Z","timestamp":1757621450608,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.urolonc.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:33:21Z","timestamp":1754404401000},"page":"596.e15-596.e21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An RMST-based analysis of systemic therapy in muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5205-8869","authenticated-orcid":false,"given":"Arjun","family":"Venkatesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudai","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reynier D.","family":"Rodriguez Rosales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Kanumuambidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Al-Toubat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hunter","family":"Sceats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelby","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bandyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-2839","authenticated-orcid":false,"given":"K.C.","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.urolonc.2025.07.002_bib0001","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/sim.6556","article-title":"Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data","volume":"34","author":"Wei","year":"2015","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.002_bib0002","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1634\/theoncologist.2016-0198","article-title":"On the interpretation of the hazard ratio and communication of survival benefit","volume":"22","author":"Sashegyi","year":"2017","journal-title":"Oncologist"},{"issue":"15","key":"10.1016\/j.urolonc.2025.07.002_bib0003","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","article-title":"Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials","volume":"34","author":"Trinquart","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2025.07.002_bib0004","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.07.002_bib0005","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1056\/NEJMc1716612","article-title":"Hazards of hazard ratios \u2014 deviations from model assumptions in immunotherapy","volume":"378","author":"Alexander","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.002_bib0006","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/annonc\/mdy075","article-title":"Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer","volume":"29","author":"Liang","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.002_bib0007","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.07.002_bib0008","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.002_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.07.002_bib0010","article-title":"Adjuvant Nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","author":"Galsky","year":"2024","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2025.07.002_bib0011","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.07.002_bib0012","article-title":"Adjuvant Pembrolizumab versus observation in muscle-invasive urothelial carcinoma","author":"Apolo","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.07.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.002_bib0014","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"unstructured":"Uno H, Tian L, Cronin A, Battioui C, Horiguchi M. survRM2: Comparing restricted mean Survival time. R package version 1.0-2. 2017. https:\/\/cran.r-project.org\/package=survRM2. Accesssed July 1, 2025.","key":"10.1016\/j.urolonc.2025.07.002_bib0015"},{"unstructured":"Centers for Medicare & Medicaid Services: 2024 ASP drug pricing files. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files. Accesssed July 1, 2025.","key":"10.1016\/j.urolonc.2025.07.002_bib0016"},{"issue":"3","key":"10.1016\/j.urolonc.2025.07.002_bib0017","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2017.07.016","article-title":"Variations in the costs of radical cystectomy for bladder cancer in the USA","volume":"73","author":"Leow","year":"2018","journal-title":"Eur Urol"},{"unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0: 2017. U.S. Department of Health and Human Services. National Institutes of Health https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on April 03, 2023).","key":"10.1016\/j.urolonc.2025.07.002_bib0018"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.002_bib0019","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdy462","article-title":"Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment","volume":"30","author":"Weir","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.07.002_bib0020","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/EDE.0b013e3181ba40eb","article-title":"How well do clinical researchers understand risk estimates?","volume":"20","author":"Falagas","year":"2009","journal-title":"Epidemiology"},{"issue":"23","key":"10.1016\/j.urolonc.2025.07.002_bib0021","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1200\/JCO.2003.06.025","article-title":"Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making","volume":"21","author":"Chao","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.002_bib0022","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JU.0000000000002953","article-title":"Cost-effectiveness of adjuvant pembrolizumab after nephrectomy for high-risk renal cell carcinoma: insights for patient selection from a Markov model","volume":"209","author":"Sharma","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.002_bib0023","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/cancers14010073","article-title":"Cost-effectiveness of immune checkpoint inhibitors in urothelial carcinoma-a review","volume":"14","author":"Walia","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.002_bib0024","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1186\/s12913-024-11138-1","article-title":"The effectiveness of visual-based interventions on health literacy in health care: a systematic review and meta-analysis","volume":"24","author":"Galmarini","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.urolonc.2025.07.002_bib0025","first-page":"ocae319","article-title":"Communicating cancer treatment with pictogram-based timeline visualizations","author":"Jambor","year":"2025","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.002_bib0026","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.amjsurg.2021.01.029","article-title":"Visual teaching aids improve patient understanding and reduce anxiety prior to a colectomy","volume":"222","author":"Stewart","year":"2021","journal-title":"Am J Surg"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.002_bib0027","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.eururo.2016.11.023","article-title":"Conflict of evidence: resolving discrepancies when findings from randomized controlled trials and meta-analyses disagree","volume":"71","author":"Sylvester","year":"2017","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:28:02Z","timestamp":1757338082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1078143925002522"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An RMST-based analysis of systemic therapy in muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}